Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments (2014 - 2023)

Esperion Therapeutics' Change in Acquisitions & Divestments history runs 9 years deep, the most recent figure standing at $17.5 million for Q2 2023.

• Quarterly Change in Acquisitions & Divestments rose 250.0% year-over-year to $17.5 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $17.5 million (down 81.18% YoY) and the FY2023 annual result came in at $42.5 million, down 37.5% from the prior year.
• Change in Acquisitions & Divestments was $17.5 million for Q2 2023 at Esperion Therapeutics, down from $25.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $45.9 million in Q1 2019 and bottomed at $2.2 million in Q3 2020.
• A 4-year average of $20.8 million and a median of $23.3 million in 2019 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments plunged 89.62% — and 2023, when it jumped 250.0%.
• Esperion Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2019, then tumbled by 55.0% to $2.2 million in 2020, then jumped by 1233.38% to $30.0 million in 2022, then sank by 41.67% to $17.5 million in 2023.
• Business Quant data shows ESPR's Change in Acquisitions & Divestments at $17.5 million in Q2 2023, $25.0 million in Q1 2023, and $30.0 million in Q4 2022.